Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 319-327

  Suksomboon, N ^a   Poolsup, N ^b   Prasit, T ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SILPAKORN UNIVERSITY   (Thailand)

Author keywords

angiotensin receptor antagonists; diabetes mellitus; insulin resistance; insulin sensitivity; systematic review; telmisartan

Indexed keywords

ADIPONECTIN; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TELMISARTAN; VALSARTAN;

ADD ON THERAPY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFECT; EDEMA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 81255190683     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01295.x     Document Type: Review

References (66)

1. Mcguire DK, Winterfield JK, Rytlewski JA, Ferrannini E, (2008) Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diabetes and Vascular Disease Research, 5, 59-66.
2. Kurtz TW, (2005) Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetologica, 2005, 42.
3. Francischetti EA, Celoria BM, Francischetti A, Genelhu VA, (2008) Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Review of Cardiovascular Therapy, 6, 280-303.
4. Kurtz TW, (2006) New treatment strategies for patients with hypertension and insulin resistance. American Journal of Medicine, 119, 24s-30s.
5. Abuissa H, Jones PG, Marso SP, O'Keefe JH, (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. Journal of American College of Cardiology, 2005, 46.
6. Scheen AJ, (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes & Metabolism, 30, 487-496.
7. Schupp M, Clemenz M, Gineste R, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocker activity. Diabetes, 54, 3442-3452.
8. Jadad AR, Moore A, Carroll C, Jenkinson C, Reynold DJM, Gavaghan DJ, McQuay HJ, (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17, 1-12.
9. Whitehead A, Whitehead J, (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Statistic in Medicine, 10, 1665-1677.
10. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Controlled Clinical Trial, 7, 177-1788.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. British Medical Journal, 327, 557-560.
12. Egger M, Davey SG, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 31, 629-634.
13. Martinez-Martin FJ, Macias-Batista A, Comi-Diaz C, Rodriguez-Rosas H, Soriano-Perera P, Pedrianes-Martin P, (2011) Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. Clinical Drug Investigation, 31, 201-212.
14. Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R, (2004) Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical Therapeutics, 26, 1228-1236.
15. Negro R, Hassan H, (2006) The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. Journal of Renin Angiotensin Aldosterone System, 7, 243-246.
16. Wohl P, Krusinová E, Hill M, et al. (2010) Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. European Journal of Endocrinology, 163, 573-583.
17. Tomiyama H, Yamada J, Koji Y, Shiina K, Yoshida M, Yamashina A, (2007) Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. American Journal of Hypertension, 20, 1305-1311.
18. Yano Y, Hoshide S, Ishikawa J, et al. (2007) The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. American Journal of Hypertension, 20, 565-572.
19. Kririttichai U, Chaisuvannarat V, (2009) Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Journal of Medical Association of Thailand, 92, 611-617.
20. Ikeda H, Minamikawa J, Nakamura Y, et al. (2009) Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAAstudy: amlodipine vs. ARB in atherosclerosis study). Diabetes Research and Clinical Practice, 83, 50-53.
21. Ikeda H, Hamamoto Y, Honjo S, Nabe K, Wada Y, Koshiyama H, (2009) Olmesartan reduced microalbuminuria in Japanese subject with type 2 diabetes. Diabetes Research and Clinical Practice, 83, 117-118.
22. Yusuf S, Diener HC, Sacco RL, et al. (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine, 359, 1225-1237.
23. Mann JF, Schmieder RE, McQueen M, et al. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet, 372, 547-553.
24. Makino H, Haneda M, Babazono T, et al. (2008) Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertension Research, 31, 657-664.
25. Bakris G, Burgess E, Weir M, et al. (2008) Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International, 74, 364-369.
26. Galle J, Schwedhelm E, Pinnetti S, et al. (2008) Antiproteinuria effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrology Dialysis Transplantation, 23, 3174-3183.
27. Yusuf S, Teo KK, Pogue J, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for cardiovascular events. New England Journal of Medicine, 358, 1547-1559.
28. Uchida H, Nakamura Y, Kaihara M, Norii H, Hanayama Y, Makino H, (2008) The MUSCAT study: a multicenter PROBE study comparing the effects of angiotensin II type 1 receptor blockers on self-monitored home blood pressure in patients with morning hypertension: study design and background characteristics. Hypertension Research, 31, 51-58.
29. Sharma AM, Davidson J, Koval S, Lacourciere Y, (2007) Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovascular Diabetology, 6, 28.
30. Bohm M, Baumhakel M, Probstfeild JL, et al. (2007) Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND). American Heart Journal, 154, 94-101.
31. Makino H, Haneda M, Babazono T, et al. (2007) Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care, 30, 1577-1578.
32. Fogari R, Derosa G, Zoppi A, et al. (2007) Effect of telmisartan- amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. American Journal of Hypertension, 20, 417-422.
33. Held C, Gerstein HC, Yusuf S, et al. (2007) Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation, 115, 1371-1375.
34. Schmeider RE, Delles C, Mimran A, Fauvel JP, Ruilope LM, (2007) Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care, 30, 1351-1356.
35. Symeonides P, Koulouris S, Vratsista E, Triantafyllou K, Ioannidis G, Thalassinos N, Katritsis D, (2007) Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. European Journal of Echocardiography, 8, 480-486.
36. Li JP, He XL, Li Q, (2006) Clinical study on treatment of early diabetic nephropathy by tangshenling combined with telmisartan. Zhongguo Zhong Xi Yi Jie He Za Zhi, 26, 415-418.
37. Barnett A, (2006) Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. Journal of the American Society of Nephrology, 17, s132-s135.
38. Makino H, Haneda M, Babazono T, et al. (2005) The telmisartan renoprotective study from incipient nephropathy-rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. Journal of Internal Medical Research, 33, 677-686.
39. Sengul AM, Altuntas Y, Kurklu A, Aydin L, (2006) Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research and Clinical Practice, 71, 210-219.
40. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine, 351, 1952-1961.
41. Teo K, Yusuf S, Sleight P, et al. (2004) Rationale, design and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combinations in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. American Heart Journal, 148, 52-61.
42. Asmar R, Gosse P, Topouchian J, N'tela G, Dudley A, Shepherd GL, (2002) Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. Journal of the Renin-Angiotensin-Aldosterone System, 3, 176-180.
43. Rippin J, Bain SC, Barnett AH, (2002) Rationale and design of diabetic exposed to telmisartan and enalapril (DETAIL) study. Journal of Diabetes and its Complications, 16, 195-200.
44. Asmar R, (2001) Effect of telmisartan on arterial distensibility and control blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus. Journal of the Renin-Angiotensin-Aldosterone System, 2 (Suppl 2), s8-s11.
45. Yusuf S, Teo K, Anderson C, et al. (2008) Effects of angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, 372, 1174-1183.
46. Hong SJ, Shim WJ, Choi JI, et al. (2007) Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-elutingstent implantation in hypertensive patients. American Journal of Cardiology, 100, 1625-1629.
47. Diener HC, Sacco R, Yusuf S, (2007) Rationale, design and baseline data of a randomised, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effctively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases, 23, 368-380.
48. Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, Lopez de Novales E, (2005) Long-term renopretective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. American Journal of Kidney Diseases, 46, 1074-1079.
49. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L, (2009) Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World Journal of Gastroenterology, 15, 942-945.
50. Cadeddu C, Piras A, Mantovani G, et al. (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. American Heart Journal, 160, 487e1-e7.
51. White WB, Littlejohn TW, Majul CR, et al. (2010) Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Pressure Monitors, 15, 205-212.
52. Bahadir O, Uzunlulu M, Oguz A, Bahadir MA, (2007) Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertension Research, 30, 49-53.
53. Ichikawa Y, (2007) Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Internal Medicine, 46, 1331-1336.
54. Nagel JM, Tietz AB, Goke B, Parhofer KG, (2006) The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism Clinical and Experimental, 55, 1149-1154.
55. Xu D, Liu J, Ji C, Zhou I, Guo H, (2007) Effects of telmisartan on hypertensive patients with dyslipidemia and insulin resistance. Journal of Geriatric Cardiology, 4, 149-152.
56. Derosa G, Cicero AF, D'Angelo A, et al. (2006) Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertension Research, 29, 849-856.
57. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R, (2004) Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertension Research, 27, 457-464.
58. Vitale C, Mercuro G, Castiglioni C, et al. (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology, 4, 6.
59. Negro R, Formoso G, Hassan H, (2006) The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. Journal of Endocrinological Investigation, 29, 957-961.
60. Derosa G, Fogari E, D'Angelo A, et al. (2007) Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics, 32, 261-268.
61. Yamada S, Ano N, Toda K, et al. (2008) Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertension Research, 31, 601-606.
62. Nakayama S, Watada H, Mita T, et al. (2008) Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetes with hypertension. Hypertension Research, 31, 7-13.
63. Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M, (2008) Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism, 57, 1473-1478.
64. Ozaki N, Nomura Y, Sobajima H, Kondo K, Oiso Y, (2010) Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. European Journal of Internal Medicine, 21, 236-239.
65. Hara K, Horikoshi M, Yamauchi T, et al. (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 29, 1357-1362.
66. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT, (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 55, 249-259.